Ensuring Clinical Safety in AI-Driven Healthcare: A Practical Guide for NHS Teams

Why this topic matters

AI's potential to augment clinical decision-making, streamline operations, and enhance patient outcomes is undeniable. From intelligent diagnostic support to predictive analytics for patient deterioration, AI solutions are rapidly advancing. However, the unique characteristics of AI – its 'black box' nature, dependence on data quality, and continuous learning capabilities – introduce novel clinical safety challenges that traditional medical devices or software might not present.

Failing to address clinical safety risks can lead to patient harm, erode trust in technology, and undermine the significant benefits AI can offer. For NHS organisations, robust clinical safety processes are not just good practice; they are a fundamental requirement under national guidelines, ensuring accountability and maintaining the high standards of patient care expected within the UK.

Practical explanation

Clinical safety, in the context of AI, refers to the practice of ensuring that AI-driven software and systems used in healthcare do not cause harm to patients. This extends beyond basic software functionality to encompass how AI interacts with human users, how it interprets and acts upon data, and its performance in real-world clinical environments.

Key aspects include:

• Regulatory Compliance: Understanding how AI software fits into existing medical device regulations (e.g., UK MDR 2002, MHRA guidance) and the growing body of AI-specific guidelines.
• Data Governance: The quality, bias, representativeness, and security of the data used to train and operate AI models are paramount. Poor data can lead to biased or incorrect outputs, posing significant risks.
• Explainability and Transparency: While not always fully 'explainable', understanding the mechanisms and limitations of an AI model is crucial for clinicians to interpret its outputs and maintain clinical oversight.
• Human-in-the-Loop: Recognising that AI tools are decision support systems, not replacements for clinical judgment. Maintaining appropriate human oversight and clear user interfaces is essential.
• Continuous Monitoring: AI models can drift in performance over time as clinical practice or patient demographics change. Ongoing monitoring and re-evaluation are critical for sustained safety.
• Clinical Risk Management: Applying established clinical safety management systems (e.g., DCB0129/0160) to AI systems, ensuring risks are identified, assessed, mitigated, and managed throughout the AI lifecycle.

Common pitfalls

NHS teams often encounter several challenges when integrating AI, which can compromise clinical safety:

• Over-reliance on Vendor Claims: Accepting a vendor's safety assurances without thorough internal validation and understanding of the AI's specific use case in your local context.
• Underestimating Data Challenges: Neglecting the profound impact of data quality, completeness, and bias (e.g., underrepresentation of specific ethnic groups in training data) on AI performance and fairness.
• Lack of Clear Clinical Pathways: Implementing AI without clearly defined clinical pathways, roles, responsibilities, and escalation procedures for AI-generated insights or alerts.
• Insufficient User Training: Deploying AI without adequately training clinical staff on its capabilities, limitations, appropriate use, and how to interpret its outputs.
• Poor Integration with Existing Systems: Standalone AI solutions that don't integrate seamlessly into existing electronic patient records or clinical workflows can lead to workarounds, errors, and missed information.
• Neglecting Post-Implementation Monitoring: Assuming an AI system remains safe and effective indefinitely after initial deployment. Performance can degrade, and new risks can emerge without ongoing vigilance.
• Absence of an AI-Specific Clinical Safety Officer (CSO): While existing CSOs are vital, a dedicated lead with expertise in AI nuances can significantly strengthen governance.

A practical framework for AI clinical safety

Adopting a structured approach is crucial for managing AI-related clinical safety. This framework aligns with existing NHS clinical safety standards and adapts them for AI.

1. Pre-procurement and initial assessment

• Define Use Case & Clinical Need: Clearly articulate the problem the AI aims to solve and its intended clinical benefit. What is the scope? Which patient group? What are the critical safety requirements?
• Vendor Due Diligence: Evaluate vendor claims, clinical evidence, regulatory status (e.g., MHRA registration as a medical device), and their safety management processes. Request safety cases, training data details, and validation reports.
• Identify Clinical Safety Leadership: Designate a clinical safety lead (AI) and establish a multidisciplinary team including clinical, IT, data, and governance experts.

2. Risk assessment and safety case development

• Hazard Identification: Systematically identify potential harms associated with the AI system, considering both software failures and human interaction errors. Use techniques like FMEA (Failure Mode and Effects Analysis) or HAZOP (Hazard and Operability Study) adapted for AI.
• Risk Analysis: Assess the likelihood and severity of identified hazards. This includes reviewing bias in training data, performance metrics (sensitivity, specificity, positive predictive value) in your local context, and potential for alert fatigue or over-reliance.
• Safety Case Development (DCB0129/0160): Develop a comprehensive safety case (DCB0129 for manufacturers, DCB0160 for deployers) detailing the system, identified hazards, risk mitigations, and residual risks. This must be a living document.
• Local Validation Planning: Plan how you will locally validate the AI's performance on your patient cohort and data, especially if different from the vendor's test population.

3. Implementation and deployment

• Clinical Workflow Integration: Design and test how the AI will integrate into existing clinical workflows. Ensure clarity on who is responsible for acting on AI outputs and how exceptions are handled.
• Staff Training & Competency: Develop and deliver comprehensive training for all users covering the AI's functionality, limitations, clinical implications, and safety protocols. Establish competency assessments.
• Data Quality & Connectivity: Ensure robust data pipelines, data quality checks, and secure connectivity. Address data migration and format compatibility issues.
• Phased Rollout: Consider a phased implementation (e.g., pilot in a single department) to identify and address unforeseen issues in a controlled environment.

4. Post-implementation monitoring and governance

• Performance Monitoring: Continuously monitor the AI's clinical performance, accuracy, and impact on patient outcomes. Track metrics related to safety (e.g., false positives/negatives leading to harm, alert overload).
• Incident Reporting: Establish clear pathways for reporting AI-related incidents, near misses, and adverse events. Integrate these into existing NHS incident reporting systems.
• Regular Review & Re-validation: Schedule periodic reviews of the safety case, risk assessments, and the AI's performance. Consider re-validation if there are significant changes to the system, its use, or underlying data.
• Stakeholder Engagement: Maintain open communication with clinicians, patients, and governance bodies regarding AI performance and safety.

Example in clinical practice

Consider an NHS Trust implementing an AI-powered system designed to predict the risk of sepsis in hospitalised patients based on real-time physiological data from the EHR.

Pre-procurement: The Trust's AI clinical safety lead and QI team work with clinical specialists to define the specific patient cohort (e.g., adult inpatients), the desired prediction horizon, and the required accuracy thresholds. They vet vendors, requesting evidence of MHRA registration, independent clinical validation, and details on training data diversity.

Risk Assessment: A multidisciplinary team identifies hazards: false negatives (missed sepsis), false positives (alert fatigue, unnecessary interventions), data input errors, and over-reliance by junior staff. The team uses DCB0160 principles to develop a safety case, outlining mitigations like mandatory human review of all AI alerts, a robust escalation pathway for high-risk predictions, and continuous clinical oversight by the medical team.

Implementation: The system is piloted on one ward. Clinicians receive training on interpreting the AI's 'risk score', understanding its limitations, and reporting any concerns. The AI is integrated into the EHR to display alerts alongside patient charts, avoiding a separate interface.

Post-implementation: The Trust's QI team monitors the system's impact: rates of sepsis diagnosis, time to treatment, and incidence of false alarms. They conduct regular audits, review incidents (e.g., if a patient deteriorates despite a 'low risk' score), and gather user feedback. The safety case is updated annually, and the AI model's performance is re-validated against local patient data to ensure it remains effective and safe for their specific population.

How Lazomis can help

Lazomis provides structured tools and frameworks that can significantly support NHS teams in managing the clinical safety of AI deployments:

• QI Project Setup: Use Lazomis to structure your AI implementation as a quality improvement project. Define clear aims, measures, and change ideas related to clinical safety, facilitating a systematic approach.
• Audit & Data Collection: Design and execute audits to monitor AI performance against clinical safety metrics (e.g., false positive/negative rates, incident reports). Collect structured feedback from users on usability and safety concerns.
• Action Planning & Tracking: Document and track actions stemming from risk assessments, incident reviews, and safety case updates. Ensure accountability and timely completion of safety-critical tasks.
• Dashboards & Reporting: Visualise key safety indicators, AI performance metrics, and incident trends. This supports continuous monitoring, informed decision-making, and reporting to governance committees.

By leveraging Lazomis, NHS teams can establish a robust, auditable, and transparent process for AI clinical safety, supporting compliance and fostering confidence in new technologies.

Key takeaways

• AI offers significant benefits but introduces novel clinical safety challenges requiring a structured approach.
• Adhere to national clinical safety standards (DCB0129/0160) and evolving AI-specific guidance from MHRA and NHS England.
• Prioritise robust data governance, local validation, and continuous monitoring of AI performance.
• Maintain a 'human-in-the-loop' approach, ensuring AI acts as a decision support tool, not a replacement for clinical judgment.
• Establish clear clinical pathways, training, and incident reporting for AI-related events.
• This resource supports, but does not replace, clinical judgement. Local policy, formulary and specialist advice should be followed.